DeCure for Arrhythmogenic right ventricular dysplasia 10
DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for arrhythmogenic right ventricular dysplasia 10 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleArrhythmogenic right ventricular dysplasia 10 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for arrhythmogenic right ventricular dysplasia 10 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A) — PRKAR1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pcgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5KJZ · 1.347 Å · ligand CYCLIC GUANOSINE MONOPHOSPHATE (PCG). Experimental structure, not a prediction.
What the evidence adds up to
Arrhythmogenic right ventricular dysplasia is a rare inherited disease characterised by right-ventricular dysfunction and ventricular arrhythmias. A 2005 review notes that most forms result from mutations in genes encoding desmosomal junction proteins, which may explain why the condition preferentially impacts the thin right ventricle. The same review states that magnetic resonance imaging, while a very sensitive tool, is also the most common reason for overdiagnosis of this condition. In the USA, most patients who meet the Task Force criteria for the disease undergo placement of an implantable cardioverter defibrillator for prevention of sudden cardiac death.
A 1997 case series of three sudden deaths describes arrhythmogenic right ventricular dysplasia as a cardiomyopathy with a normal or mild increase in heart weight and right-sided heart dilatation, where a proportion of the right ventricular muscle is replaced by fat and fibrous tissue. The condition is characterised clinically by episodes of ventricular tachycardia and global dyskinesia of the right ventricle, and may cause ventricular fibrillation and sudden death, especially in young persons engaged in strenuous exercise or who experience severe emotional outburst. The aetiology was noted to be unknown, although familial clustering was observed in some cases.
A 2015 lecture reviewed the history, mechanisms, and pathogenesis of the disease, focusing on electrophysiological changes, and discussed how this knowledge has modified the clinical approach to care. No specific drug therapy is mentioned in any of these abstracts.
What is still missing is any randomised trial of a pharmacological intervention for this disease, a clear stratification of patients by genotype or phenotype to guide therapy, and dedicated funding for drug-repurposing studies in this rare condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Cardiology · 2005 · 95 citations
AbstractPURPOSE OF REVIEW: Arrhythmogenic right-ventricular dysplasia is a rare inherited disease characterized by right-ventricular dysfunction and ventricular arrhythmias. The purpose of this article is to review recent developments concerning the diagnosis, genetics, and management of patients with this disease. RECENT FINDINGS: In the past few years important new information has emerged regarding the role of magnetic resonance imaging in the diagnosis of arrhythmogenic right-ventricular dysplasia. Although magnetic resonance imaging is a very sensitive tool, it is also the most common reason for over diagnosis of this condition. There have also been important new breakthroughs in the genetic basis of arrhythmogenic right-ventricular dysplasia; it now appears that most forms result from mutations in genes encoding desmosomal junction proteins. This may explain why arrhythmogenic right-ventricular dysplasia preferentially impacts the thin right ventricle. Other studies have demonstrated the important role of implantable cardioverter defibrillator therapy in the management of patients with arrhythmogenic right-ventricular dysplasia. In the USA, most patients who meet the Task Force criteria for the disease undergo placement of an implantable cardioverter defibrillator for prevention of sudden cardiac death. SUMMARY: Arrhythmogenic right-ventricular dysplasia is a rare disease. Recent new findings concerning the diagnosis and management of these patients should have direct implications regarding the evaluation and management of patients with this rare, but potentially life-threatening, disorder.
4. Arrhythmogenic Right Ventricular Dysplasia (ARVD): An Overlooked and Underdiagnosed Condition?
AbstractWe present three cases of arrhythmogenic right ventricular dysplasia causing or contributing to sudden death. These cases serve to highlight the range of clinical presentations and histological features seen in this rare and poorly understood condition. Arrhythmogenic right ventricular dysplasia (ARVD) is a cardiomyopathy characterized by a normal or mild increase in heart weight with right-sided heart dilatation. Typically a proportion of the right ventricular muscle is replaced by fat and fibrous tissue. Clinically, the condition is characterized by episodes of ventricular tachycardia and global dyskinesia of the right ventricle. It may cause ventricular fibrillation and sudden death, especially in young persons engaged in strenuous exercise or who experience severe emotional outburst. The aetiology of the condition is unknown, although it has been noted to show familial clustering in some cases.
Newer Diagnostic and Treatment Options for Patients With ARVC
AbstractThe Intercontinental Lecture, presented by Dr Melvin M. Scheinman, discusses arrhythmogenic right ventricular dysplasia (ARVC). The presenter reviews the history, mechanisms, and pathogenesis of ARVC, with a focus on electrophysiological changes, and then discusses how this new knowledge has modified the clinical approach to the care of this disease.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
